A Phase 3 interventional study of Hetrombopag Olamine and Hetrombopag Olamine; Hetrombopag Olamine Placebo in Patients With Chemotherapy-Induced Thrombocytopenia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 51 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment
Bulgaria, China, France, Italy, Poland, Romania, South Korea, Spain, Turkey (Türkiye), Ukraine
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Thrombocytopenia with a site in United States — 18 open to participants now, 21 under way, 3 of them phase 3. Thrombocytopenia · United States.
Among the 177 studies in Thrombocytopenia with a site in United States, this one is the 24th largest by planned enrollment of the 136 interventional ones that give a count, is one of 6 that started in 2026, is one of 26 in phase 3, reaches primary completion later than 13 of the 19 other live ones, and was the 173rd registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →18 of the 177 studies in Thrombocytopenia with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
NICHD Neonatal Research Network · Sites in United States
Ages 1 hrs–48 hrs · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–85
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Rushad Patell · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 74 · Phase 3 31 · Phase 4 5
First in 1993; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 35 across the 136 interventional studies, 100 across the 36 observational. Of the 142 that completed or were terminated, 75 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 177 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 5 studies filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
5 of the studies in Thrombocytopenia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06223607Methodist Health SystemDual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia | 2026-12-28 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
| NCT05711485Johns Hopkins Bloomberg School of Public HealthPlatelet-Directed Whole Blood Transfusion Strategy for Malaria | 2027-04-30 |
| NCT05980806Karyopharm Therapeutics IncA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | 2027-06 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 177 studies in Thrombocytopenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
The criteria were revised on the registry on Oct 1, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Hetrombopag Olamine
Drug: Hetrombopag Olamine; Hetrombopag Olamine Placebo
For Part A, all participants would receive hetrombopag treatment.
For Part B, participants would be randomized to receive hetrombopag treatment or matching placebo, respectively.
Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months.
Time frame: around 6 months.
Part A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months.
Time frame: around 6 months.
Part A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months.
Time frame: around 6 months.
Part B: A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years.
Time frame: around 3 years.
Part B: No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until the end of the primary treatment period, around 3 years.
Time frame: around 3 years.
Part B: Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years.
Time frame: around 3 years.
Proportion of participants achieving platelet count ≥100×109/L without the use of rescue therapy within 14 days after initiating the investigational product treatment, around 3 years.
Time frame: around 3 years.
Platelet count nadir from Cycle 1 Day 1 until the primary treatment period, around 3 years.
Time frame: around 3 years.
Proportion of participants free from serious bleeding events, during the treatment period from the initiation of IP treatment until the primary treatment period, around 3 years.
Time frame: around 3 years.
Proportion of participants with neutropenia during the treatment period from the initiation of IP treatment until the primary treatment period, around 3 years.
Time frame: around 3 years.
Number of Adverse Events/Serious Adverse Events, safety lab parameters, vital signs, etc within study period, around 3 years.
Time frame: around 3 years.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.
Of 29 phase 3 interventional studies under Thrombocytopenia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 45. This study's planned 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
Bulgaria, China, France, Italy, Poland, Romania, South Korea, Spain, Turkey (Türkiye), Ukraine
Bulgaria, China, France, Italy, Poland, Romania, South Korea, Spain, Turkey (Türkiye), Ukraine
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hetrombopag olamine
Jiangsu HengRui Medicine Co., Ltd. →